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Abstract
Intracellular-acting peptide drugs are effective for inhibiting cytoplasmic protein targets, yet face
challenges with penetrating the cancer cell membrane. We have developed a lipid nanoparticle
formulation that utilizes a pH-sensitive calcium carbonate complexation mechanism to enable the
targeted delivery of the intracellular-acting therapeutic peptide EEEEpYFELV (EV) into lung
cancer cells. Lipid-calcium-carbonate (LCC) nanoparticles were conjugated with anisamide, a
targeting ligand for the sigma receptor which is expressed on lung cancer cells. LCC EV
nanoparticle treatment provoked severe apoptotic effects in H460 non-small cell lung cancer cells
in vitro. LCC NPs also mediated the specific delivery of Alexa- 488-EV peptide to tumor tissue in
vivo, provoking a high tumor growth retardation effect with minimal uptake by external organs
and no toxic effects.
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1. Introduction
Rapid biotechnological growth has made it possible to design therapeutic macromolecules
against specific molecular targets [1, 2, 3]. However, the cellular internalization of
hydrophilic therapeutics is limited by the hydrophobic interior environment of the
phospholipid cellular membrane. Appropriate delivery vectors are necessary to successfully
deliver hydrophilic therapeutics to the cell interior.
Intracellular therapeutic peptide delivery is a particularly appropriate strategy for treating
cancer; a disease where aberrant cellular proliferation and evasion of apoptotic signaling is
mediated by the over-expression of certain characteristic protein factors [4, 5]. Although
most peptide anti-cancer drugs act on the extracellular surface of cancer cells, several
peptide therapeutics have been developed for intracellular targeting that make use of a cell
penetrating peptide (CPP) vector such as TAT, Antennapedia or Polyarginine [6, 7, 8, 9].
These CPP-protein therapeutic conjugates, however, are difficult to manufacture efficiently,
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encounter challenges in drug-carrier separation, demonstrate limited targeting selectivity,
and can cause systemic toxicity [10, 11, 12].
A successful delivery system for transport of intracellular-acting cancer peptide drugs
should provoke a long peptide circulation time, maintain the biological activity and stability
of the peptide, target the peptide to the tumor site, mediate the uptake of the peptide into the
target cancer cells, and successfully release the peptide drug to the cell cytoplasm [13].
Given this criteria, nanoparticles serve as particularly good vector mechanisms for cancer
therapeutic transport because their advantageous size allows them to be sequestered in tumor
cells due to the enhanced permeability and retention (EPR) effect. Small (<100 nm) particles
can successfully penetrate into the characteristic leaky vasculature of tumors where they are
retained in dense internal connective tissue [14, 15, 16, 17]. PEGylated NPs, in particular,
have also shown success at evading parts of the reticuloendothelial system (RES),
concentrating NP uptake in the tumor tissue [18, 19].
We have previously delivered siRNA and an anionic therapeutic peptide into the cytoplasm
of H460 lung cancer cells by encapsulating the respective drugs into a membrane/core lipid
nanoparticle (NP) [5, 18]. Although this particle successfully delivered the encapsulated
therapeutic, NP release of the peptide drug within the cytoplasm did not significantly occur.
We postulate that the poor drug release was a result of increased retention of the dissociated
peptide or protein-encapsulating NPs in the cellular endosome [20]. Recently, we have
developed a lipid-apolipoprotein NP platform to successfully deliver a cytochrome c
therapeutic peptide conjugated with a membrane-permeable-sequence (MPS) to the
cytoplasm of lung cancer cells [21]. Delivered cytochrome c provoked massive cell
apoptosis in vitro and resulted in marked tumor growth retardation in vivo, demonstrating
proof-of-concept for the potential of nanoparticles to act as potent peptide drug carriers.
It has been reported that calcium phosphate (CaP) and calcium carbonate (CC) can be used
to form liposomal NP complexes and facilitate drug delivery [19, 21, 22]. Unlike some
polymeric NP platforms, liposomal CC (LCC) particles cause a strong proton sponge effect
in the low endosomal pH, resulting in endosomal lysis and rapid dissociation of the NPs into
the cell cytoplasm. LCC NPs can also be conjugated with targeting ligands, such as
anisamide; a molecule specific to the sigma receptor over-expressed in lung cancer cells.
EEEEpYFELV (EV) is a nonapeptide mimicking the Y845 site of EGFR, a receptor tyrosine
kinase which is responsible for STAT5b phosphorylation. The silencing of this characteristic
EGFR pathway should lead to diminished EGFR-initiated cell proliferation and increased
lung cancer cell apoptosis [5]. In this paper, we will detail the successful encapsulation of
the EV peptide in pH-sensitive liposomal calcium carbonate NPs conjugated with an
anisamide targeting ligand. We will demonstrate that our LCC NP mediates the successful
delivery and release of the EV peptide inside the cytoplasm of H460 non-small cell lung
carcinoma cells. We will also show the tumor targeting and therapeutic effect of the LCC
NP in an H460 xenograft mouse model.
2. Materials and Methods
2.1. Materials
1,2-dioleoyl-3-trimethylammonium-propane chloride salt (DOTAP), cholesterol, and 1,2-
distearoryl-sn-glycero-3-phosphoethanolamine-N-[methoxy (polyethyleneglycol-2000)]
ammonium salt (DSPE-PEG) were purchased from Avanti Polar Lipids, Inc. (Alabaster,
AL). DSPE-PEG-anisamide (AA) and DOPE-glutaric acid were synthesized in our lab
(Supplemental Fig. 1). Therapeutic phosphorylated EV peptide (EEEEpYFELV) and control
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EE scrambled peptide (EpYELFEEVE) were synthesized commercially (Peptide 2.0 Corp.
VA). Other chemicals were obtained from Sigma-Aldrich (St. Louis, MO) without further
purification.
2.2. Preparation of the LCC-PEG-AA NP
A schematic illustration of the LCC nanoparticle preparation incorporating the EV peptide is
shown in Figure 1a. The anionic lipid-coated CC core was prepared with a water-in-oil
emulsion method. Briefly, 18 μL of 3% sodium carbonate buffer (pH 8.3) was mixed with
the same volume of peptide (2 mg/mL) and was dispersed in 1 mL of a cyclohexane to form
a well dispersed water-in-oil emulsion. The calcium solution was prepared by adding 20 μL
of a calcium chloride solution (250 mM) to 1 mL of a cyclohexane oil phase. A 25 μL
volume of a 25 mg/mL 1,2-dioleoyl-sn-glycero-3- phosphoethanolamine-N-(glutaryl)
(DOPE-glu) solution dissolved in chloroform was added to the calcium phase. After mixing
the above two solutions by sonication (15 sec, 3 times), the mixture was centrifuged at 8,000
× g for 1 min to remove the cyclohexane and excess surfactant. The core pellets were
dispersed in 500 μL of water for liposomal formation with DOTAP/cholesterol (10 mg/mL).
The LCC nanoparticles were further modified with 50 uL of DSPE-PEG-2000 (10 mg/mL)
or DSPE-PEG-AA (10 mg/mL). The particle size and zeta potential of the finished LCC NPs
were detected in 1 mM KCl using a Malvern ZetaSizer Nano series (Westborough, MA). To
measure the loading efficiency of the EV peptide, free EV peptide labeled with Alexa-488
was measured after elimination of unreacted free Alexa-488 and unconjugated EV peptide
using a dialysis membrane (MW: 2000). Transmission electron microscopy (TEM) images
of the LCC NPs were acquired with the use of a JEOL 100CX II TEM (JEOL, Japan). The
TEM sample of LCC NPs was prepared on a 300 mesh carbon coated copper grid (Ted
Pella, Inc., Redding, CA).
2.3. Disruption of the LCC calcium carbonate core under various pH conditions
Calcium carbonate cores were formulated with the EV therapeutic peptide to evaluate
whether the calcium complex core rapidly dissociates at a low pH condition. CC cores were
added to 0.1 M sodium phosphate buffers of different pH levels (5.5, 6.5 and 7.4). To
observe the core disruption, the intensity per second of the nanoparticle solutions was traced
using a Malvern ZetaSizer Nano series (Westborough, MA) after incubation of the samples
in the respective pH buffers for 30 min. Decreases in particle intensity represented
disruption of the inner LCC core. The experiment was duplicated and the data was expressed
as a mean average intensity with the standard deviation also represented as error bars.
2.4. Release profile of fluorescently-labeled EV peptide from LCC-PEG-AA NPs under
different pH conditions
LCC-PEG-AA NPs encapsulating Alexa-488-EV were incubated for 5 min in 500 μL of
phosphate buffers adjusted to different pH levels. Samples were then spun down and the
supernatant containing released EV peptide was separated from the NP material pellet and
was loaded into a tricine/SDS PAGE gel [5]. After running the samples, the gel was
visualized using a Kodak imaging system “FX Pro” for examination of the fluorescence
peptide bands released from LCC.
2.5. Cellular uptake of EV in LCC-PEG-AA NPs
NCI-H460 human non-small cell lung carcinoma cells were obtained from ATCC
(Manassas, VA). The cells were maintained in RPMI 1640 cell culture medium with 10%
fetal bovine serum (Invitrogen, Carlsbad, CA), 100 μg/mL penicillin, and 100 μg/ml
streptomycin (Invitrogen, Carlsbad, CA). H460 cells were previously shown to be sigma-1
receptor positive and to have a moderate level of EGFR protein expression [23, 24]. H460
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cells (1 × 105 per well) were seeded in 24-well plates (Corning Inc., Corning, NY) under
covered glass for 12 h before treatment. Cells were then treated with a 100 nM final
concentration of different LCC formulations at 37 °C for 3 h. After two PBS wash cycles,
cells were fixed with 2% paraformaldehyde for 10 min and nuclei were counterstained with
DAPI (Sigma). Cells were imaged with use of a Leica SP2 confocal microscope (Leica,
Bannockburn, IL).
2.6. MTT cellular proliferation assay for determination of H460 cell viability after EV in LCC-
PEG-AA NP treatment
H460 cells (5 × 105) were incubated with 1 μM of various LCC nanoparticle formulations
for 12, 24 or 36 h. At each time interval, cell viability was measured using an MTT assay
(Sigma-Aldrich, St. Louis, MO) with lysed cells as a negative control and untreated cells
serving as a positive control.
2.7. Flow cytometry for detection of H460 cell apoptosis caused by EV in LCC-PEG-AA NP
treatment
Discrimination of apoptotic cellular subpopulations was evaluated using flow cytometry
after treatment of H460 cells (5 × 105) with 2 μM of various LCC nanoparticle formulations
for 36 hours. After treatment, cells were washed with a binding buffer (10 mM HEPES, pH
7.4, 150 mM NaCl, 5 mM KCl, 1 mM MgCl2, 1.8 mM CaCl2). Collected samples were then
suspended in 50 μL of calcium binding buffer and 3 μL of Annexin V-FITC (0.5 mg/mL)
was added to each sample. After washing with PBS buffer, cells were suspended in 500 μL
of calcium binding buffer and PI (5 mg/mL) was added to the solution. Cells were
immediately analyzed using a BD FACS Canto™ flow cytometer (BD biosciences, San Jose,
CA).
2.8. Tissue distribution of the EV in LCC-PEG-AA NPs in vivo
Female nude mice 5–6 weeks of age were purchased from NCI. All work performed on
animals was in accordance with the standards of the IACUC committee. NCI-H460 cells (5
× 106 cells) were introduced by intracutaneous injection to the rear side on the back of nude
mice. When the tumor measured 0.5 to 0.8 cm in diameter, different formulations of
Alexa-488 labeled-EV in LCC-PEG-AA NPs were i.v. injected in the mice (400–500 μg/kg)
via the tail vein. After 4 h, the mice were sacrificed and their tissues collected and imaged
by the IVIS™ Imaging System (Xenogen Imaging Technologies, Alameda, CA). The total
average fluorescence intensity of the tumors from each mouse group was quantified using
Image J software (tumor area x fluorescence intensity).
2.9. In vivo tumor growth regression after EV in LCC-PEG-AA NP treatment
The NCI-H460 xenograft (40–50 mm2) tumor bearing mice were produced on the 6th d after
intradermal injections of 5 × 106 cells in the back side of nude mouse. The mice were
randomly assigned to different treatment groups (n=5~6 for each group) and were tail-vein
injected every other day with various formulations of EE or EV in LCC-PEG-AA NPs (0.36
mg/kg). Tumor growth was monitored every 2 days thereafter and, at the end of the
experiment, all mice were sacrificed by cervical dislocation.
2.10. In vivo toxicity of EV in LCC-PEG-AA NPs in CD-1 mice
CD-1 mice were randomly divided into 4 groups with 5 mice in each group. The first group
was designated as a control group that was i.v. injected with PBS only. The second group
was injected with 0.36 mg/kg of free EV peptide. The other two groups were injected with
0.36 mg/kg of EV peptide or EE peptide in various LCC NP formulations, respectively. All
treatments were injected in the mice every other day for 10 days. Tumor size in each mouse
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was measured with a caliper. Two days after the last injection of LCC formulation (Day 16
in Fig. 7), blood samples were collected from the retroorbital puncture and were analyzed
immediately for serological parameters. The blood sample tubes were centrifuged at 12,000
rpm at 4°C for 10 min, and were then stored at −20°C until analysis for serological
parameters could be performed. The serological parameters measured included the
following: alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline
phosphatase (ALP), creatine, BUN (blood urine nitrogen), sodium and calcium levels.
2.11. Statistical analysis
Data is expressed as mean ± SEM and was analyzed using Microsoft Excel (office 2007)
and Sigma plot Ver. 10 software. Statistical analysis was performed using a one-way
Analysis of Variation (ANOVA) followed by Dunnett-test for differences among treatment
groups (Keyplot ver 2.0 software). Values of P<0.05 were considered significant.
3.0 RESULTS
3.1 Characterization of LCC nanoparticle
The calcium carbonate LCC core demonstrated a slightly negative zeta potential (−5 to −10
mV). Size and zeta potential analysis of the complete LCC NPs determined that the NPs
exhibit a 50–70 nm diameter and a positive +15 mV zeta potential. The zeta potential
difference between the final particle and the LCC core can be attributed to the additional
positive charge of the DOTAP/cholesterol external LCC core coating. TEM analysis
confirmed that LCC NPs are spherical in shape with a dark calcium carbonate core and an
average diameter of 60–70 nm (Fig. 1b). The LCC-PEG-AA NP encapsulation efficiency of
Alexa-488 fluorescently-labeled EV peptide was determined to be 65–70% by incubating
the particles in different pH buffers and analyzing the released EV quantity on an SDS-
PAGE gel. The quantity of peptide, calcium and surfactant in the LCC nanoparticle was
optimized at a final respective proportion of 1:180:25 to maximize the simultaneous
liposomal encapsulation of both the EV peptide and the calcium carbonate core.
3.2. Disruption of LCC core and release of Alexa-488 fluorescently-labeled EV peptide in
different pH environments
LCC core, prepared without the addition of the DOTAP/cholesterol external liposomal layer,
was exposed to different pH environments to evaluate the release of fluorescently-labeled
EV peptide in an acidic environment representative of the cellular endosome. As shown in
figure 2a, LCC cores rapidly dissociate at a low 5.5 pH within five minutes and moderately
dissociate at a pH 6.5 condition. It was also determined that the LCC core is stable with
negligible breakdown at a pH of 7.4. We verified whether the observed LCC dissociation
translates into increased release of the encapsulated Alexa-488 fluorescently-labeled EV
peptide. At a pH of 7.4, negligible EV release was observed from sample solutions
visualized on a SDS page gel (Fig. 2b). Overall, a pH-dependent trend was observed; greater
EV peptide band saturation occurred in LCC NP samples that were incubated in a lower pH
environment. The EV peptide band released from LCC NPs at a pH of 5.5 was 3 times
stronger than the fluorescent band obtained from LCC NPs incubated at a pH of 6.5.
3.3. Uptake of LCC NPs encapsulating Alexa-488 fluorescently-labeled EV peptide by H460
cells
H460 cells incubated with LCC-PEG-AA NPs encapsulating Alexa-488 fluorescently-
labeled EV peptide demonstrated significant NP uptake and EV localization in the cell
cytoplasm (Fig. 3b) when compared to H460 cells treated with free Alexa-488 labeled EV
peptide (Fig 3a).
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3.4. Inhibition of H460 cell proliferation induced by EV in LCC-PEG-AA NPs
H460 cells treated with 1 μM of the EV peptide encapsulated in LCC-PEG-AA NPs showed
a significant 40% reduction in viability compared to an untreated control after 36 h of NP
treatment (Fig. 4). In comparison, H460 cells treated with LCP-PEG-AA NPs formulated
with the scrambled EE peptide showed a slight 10–12% reduction in cell viability compared
to an untreated control. Previously, we have documented that this decrease could be
attributed to a mild cytotoxic effect provoked by intracellular delivery of EE [5].
3.5. Apoptotic induction and cell cycle arrest provoked by EV-encapsulating LCC NPs
H460 cells were treated with 2 μM of either the EV or EE peptide in different LCC
formulations for 36 h, then the cytotoxic effect of each treatment was evaluated by Annexin
V/PI staining and flow cytometry (Fig. 5). As shown by the combined Q4 and Q2 quadrants
of each distribution chart, indicative of early and late apoptotic induction, respectively,
H460 cells underwent massive apoptosis (70–80%) after treatment with LCC-PEG-AA NPs
encapsulating the EV peptide. In comparison, only about 15% of H460 cells treated with the
scrambled EE peptide delivered with either LCC-PEG or LCC-PEG-AA showed apoptotic
induction. LCC NPs formulated with EV in the absence of PEG-AA showed a marked
decrease in cell targeting, indicating that PEG-AA improves the therapeutic efficacy of the
LCC NP in vitro.
3.6. In vivo tissue distribution of the EV formulated in LCC-PEG-AA NPs
Nude mice bearing an H460 tumor xenograft were i.v. injected with various formulations of
LCC NPs encapsulating a fluorescently-labeled, Alexa-488 EV peptide to evaluate the NP
distribution in vivo. Mice treated with LCC NPs including DSPE-PEG showed little
fluorescence in the liver and a comparatively greater intensity in the tumor (Fig. 6). NPs
produced with DSPE-PEG-AA provoked an even greater tumor fluorescence, with the
majority of experimental mice showing no significant fluorescence elsewhere in the body.
This data suggests that the tumor was the major site of peptide uptake. This observation is
supported by an estimate of the total fluorescence intensity of the tumors from each
treatment group (Fig. 6b). Mice treated with EV in LCC-PEG-AA showed a dramatically
higher amount of Alexa-488 EV peptide retention compared to mice treated with free EV
peptide.
3.7. In vivo tumor growth retardation effect after treatment of H460 xenograft mice with EV
formulated in LCC-PEG-AA NPs
We examined whether the EV in LCC-PEG-AA NPs was able to provoke anti-tumor effects
after systematic i.v. injection. Figure 7 clearly illustrates a dramatically significant reduction
in tumor growth after mouse treatment with EV-encapsulating, LCC-PEG-AA NPs.
Xenograft mice treated with free EV peptide or LCC-PEG-AA NPs encapsulating EE
peptide showed no significant tumor growth reduction compared to tumor growth observed
in mice treated with PBS.
3.8. Serological toxicity evaluation of EV formulated in LCC-PEG-AA NPs
Biochemical parameters, including AST, ALT and ALP, were measured at the completion of
NP treatment to evaluate the toxic effect of the EV in LCC-PEG-AA NPs on the liver (Table
1). All measured serological values of the EV in LCC-PEG-AA treated mice were similar to
those of the control group. This result demonstrates that there are no significant, prolonged
systematic toxic effects induced by EV formulated in LCC-PEG-AA NPs.
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Delivery of an intracellular-acting therapeutic by route of receptor mediated endocytosis is
difficult because drug carriers often cannot both maintain integrity when trapped inside an
endosome and mediate endosomal release of the drug cargo into the cell cytoplasm. It has
been shown that cationic drug-carrying polymers enriched with secondary and tertiary
amino groups can induce endosomal accumulation of chloride ions, subsequently leading to
the rupture of the endosome membrane by increased osmotic pressure, a phenomenon
known as the “proton sponge effect” [25]. However, cationic polymers also provoke highly
toxic effects, limiting their potential as therapeutic vectors in vivo.
In a previous study, we developed an LPH nanoparticle using cationic protamine to facilitate
the delivery of EV peptide into the cytoplasm of H460 cells in vivo [5]. Although the LPH
NP was able to successfully penetrate into the cell, minimal EV endosomal release was
observed. We have developed the LCC NP, including a calcium complex core, as a
completely different delivery system to facilitate improved peptide endosomal release and
increased therapeutic efficacy.
Our NP platform operates using a phenomenon similar to the proton sponge effect used to
free ingested NPs from the endosome. Compared to the LPH EV NP, the LCC EV NP
includes a markedly different type of composition, including an inner calcium core and an
overall more compact size. As shown in figure 1a, calcium carbonate can mediate the
formation of calcium complexes which are able to tightly bind to negatively charged
therapeutics, such as the EV peptide, due to the high affinity of the calcium ions for the
carbonyl groups. The LCC NP encapsulates these calcium-drug complexes with an anionic
lipid DOPE-glu acting as a surfactant. Figure 1b depicts the homogenous spherical shape
and size of the produced LCC NPs which are manufactured with a dense internal calcium
core and a faint outer lipid coating.
We postulate that upon receptor-mediated ingestion of our LCC NPs, the calcium complex
should moderate an increase of calcium and bicarbonate/carbonate ions in the acidic
endosomal environment, causing osmotic swelling. This effect would serve as a novel
mechanism facilitating NP escape from the endosome and subsequent drug release to the
cytoplasm. To test this concept, we exposed the EV in LCC-PEG-AA NPs to different acidic
environments and measured the dissociation of the internal calcium complex encapsulating
fluorescently-labeled EV peptide. The LCC calcium core complex was easily dissociated in
a low pH buffer, releasing EV peptide in a pH-dependent manner (Fig. 2a). At a 5.8 acidic
pH representative of the endosomal environment, fluorescently-labeled EV peptide was
released from fully formed LCC-PEG-AA NPs in significantly greater amounts than
observed at more basic pH levels. Importantly, at a pH of 7.4, a pH condition representative
of the bloodstream, negligible core dissociation was detected.
This calcium complex core dissociation and release process may have been aided by the
DOTAP/cholesterol lipid coat surrounding the DOPE-glu-calcium complex. Before the
addition of DOTAP/cholesterol, the calcium carbonate core should be coated with DOPE-
glu because the glutamic acid headgroup of DOPE-glu readily interacts with calcium ions.
During the formation of the LCC NP, DOTAP/cholesterol should further coat the core to
form the outer leaflet of the coating lipid bilayer, resulting in stable NPs in an aqueous
solution. When the LCC NPs disassemble in the endosome, the cationic lipid DOTAP may
form ion-pairs with the anionic endosomal lipids, leading to further destabilization of the
endosome and the release of peptide cargo into the cytoplasm. The conversion of the LCC’s
carbonate to bicarbonate and, finally, to carbon dioxide, may also have provoked additional
stress leading to a rupture in the cellular endosome.
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The ability of the LCC NP to enter cancer cells and localize in the cell cytoplasm was also
demonstrated. As shown by figure 3b, treatment of H460 non-small cell lung carcinoma
cells with LCC-PEG-AA NPs resulted in cell uptake and detection of the encapsulated
fluorescently-labeled EV peptide in the cell cytoplasm. Successful EV peptide delivery and
release into the cytoplasm should induce a therapeutic effect, as EV peptide has been shown
to inhibit the phosphorylation of STAT5b [5]. Indeed, figure 4 demonstrates a 40% decrease
in H460 cell viability after 36 h of treatment with 1 μM of EV in LCC-PEG-AA NPs. H460
cells treated with LCC-PEG-AA showed not only diminished viability, but also a significant
increase in apoptosis compared with control formulations (Fig. 5). This indicates that LCC-
PEG-AA NPs can facilitate the transport of EV peptide to the cytoplasm where it can
interact with its molecular target: the kinase domain of EGFR. It should be noted that LCC-
PEG-AA treatment provoked a significant decrease in cell viability at a final dosed EV
concentration of 1 μM (Fig. 4). Previously, it has been shown that the IC50 of free EV
peptide for inhibiting EGFR activity is about 2 μM [5]. Our result, therefore, implies that
LCC-PEG-AA NPS are highly permeable through the cell membrane, provoking more
efficient cell uptake and eventual endosomal release of EV when compared to cell uptake of
free EV peptide.
In an H460 xenograft mouse model, the LCC-PEG-AA NP demonstrated significant tumor
targeting ability, specifically delivering fluorescently-labeled EV peptide to the tumor (Fig.
6a). This tumor targeting effect was partly the result of DSPE-PEG-AA addition to the LCC
NP. Sigma receptor is a marker for epithelial cells and is over-expressed in many human
lung cancer cells [24, 26, 27, 28]. DSPE-PEG-AA, which contains an anisamide targeting
moiety against the sigma receptor, facilitates the specific binding of NP to tumor cells [24].
Indeed, mice treated with NPs formulated without the anisamide targeting ligand showed
less EV peptide tumor uptake than mice treated with EV in LCC-PEG-AA NPs (Fig 6b).
The therapeutic advantage of the anisamide targeting ligand was more pronounced in an
H460 xenograft tumor growth inhibition analysis (Fig. 7). H460 xenograft mice treated with
PBS, free EV peptide, or EE in LCC-PEG-AA NPs all showed no significant tumor growth
inhibition. In comparison, mice treated with EV in LCC-PEG-AA NPs witnessed a
significant decrease in tumor growth over two weeks. Importantly, serological proteins and
other factors collected from mice treated with NP formulations were consistently normal,
indicating low in vivo toxicity (Table 1). The normal levels of biochemical parameters
assessing liver integrity, such as AST, ALP and ALKP, especially indicate the safety of the
LCC-PEG-AA NP system.
Overall, our current LCC formulation compares favorably with the previous LPH
(Liposome-Protamine-Heparin) formulation which was also used to deliver the EV peptide
[5]. The major compositional difference between the two involves the addition of a calcium
core for drug encapsulation in the LCC NP. The LPH protamine-heparin complex can
readily encapsulate a negatively charged peptide such as EV, yet the loaded NP is not highly
sensitive to environmental conditions affecting cargo release. The LCC’s calcium-carbonate
core, however, is acid sensitive (Fig. 2) with the ability to moderate a more controlled cargo
release at the pH condition commonly found in endosomes. We believe that this acid
sensitivity facilitates an increased endosomal release of the EV peptide from the LCC NPs
inside tumor cells compared to the intracellular release of EV from LPH NPs.
In addition, the pH-sensitivity may delay the release of EV peptide from the LCC NPs at
higher pHs in the bloodstream, as shown by figure 2, concentrating EV peptide release to the
intracellular compartments of targeted cancer cells. Using the same in vivo model as
observed in the LPH study, figure 6 clearly shows that EV peptide delivered by LCC-PEG-
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AA NPs is concentrated mainly within tumor cells, with some treated mice showing no EV
retention in the liver.
In a previous paper, we show that the EV therapeutic peptide has an IC50 of about 2 μM in
inhibiting EGFR kinase, and that the LPH NPs were able to deliver sufficient EV to reach a
similar intracellular concentration [5]. Although one expects that the LCC NP will deliver
more EV intracellularly than the LPH NP, similar efficacy in tumor growth retardation was
observed for both formulations ([5] and Fig. 7 in the current manuscript). One possible
reason for the apparent discrepancy is that the LCC NP has already delivered EV to a
concentration approximately equal to the IC50 of the drug. Further increase of intracellular
EV concentration resulting from LCC delivery would not cause any significant enhancement
in tumor growth inhibition.
The most important improvement of the LCC NP involves its potential ability to encapsulate
a variety of drugs based on a reverse-emulsion preparation of the internal core. In
comparison, the LPH NP relies on charge-charge interaction to capture its cargo, severely
limiting the LPH loading capacity of non-highly charged drugs. Overall, compared to the
LPH NP, the LCC NP demonstrates a more compact size, an increased pH-controlled
peptide-carrier separation (translating to improved intracellular endosomal release), a highly
successful tumor growth retardation arrest, a favorable biodistribution, and a more inclusive
outlook for delivering non-highly charged therapeutic peptides. The LCC formulation,
therefore, improves upon all of the beneficial therapeutic and targeting properties of the
LPH system with additional platform flexibility and an expanded therapeutic scope.
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Schematic illustration of LCC nanoparticle preparation (a) and TEM imaging of unstained
LCC-PEG-AA NPs (b).
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Stability of the pH sensitive calcium carbonate core studied at 5, 10, 15, 20, 30 and 45 min
exposure to different pH conditions (pH 5.5, 6.5 or 7.4). The disruption of the formation of
calcium cores was measured using dynamic light scattering (average mean value of detected
particle intensity per second (%)) (a). Release profiles of Alexa-488-EV peptide formulated
in LCC-PEG-AA NPs under different pH conditions were observed by SDS-PAGE analysis
followed by imaging with a KODAK imaging system (b).
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EV Peptide uptake by H460 cells. Uptake of Alexa-488-EV peptide formulated in LCC-
PEG-AA NPs was observed by confocal microscopy, 40X (b). Free Alexa-488-EV peptide
treated cells were used as the comparative control (a).
Kim et al. Page 13














MTT assay of H460 cell viability after treatment with 1 μM of EV or EE formulated in
LCC-PEG-AA NPs for different incubation time intervals (12, 24 and 36 h). Viabilities were
calculated as compared to an untreated control at each time point. P < 0.05 *.
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Cellular apoptosis of H460 lung cancer cells evaluated by flow cytometry. Cells were
treated for 36 h with 2 μM of EE or EV peptide formulated in either LCC-PEG NPs or
LCC-PEG-AA NPs. A control sample was treated with PBS buffer (pH 7.4). Apoptotic cells
(early and late apoptosis) were quantified (right lower panel). P < 0.05 *.
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Tissue distribution of EV peptide. Major organs were taken from H460 tumor bearing mice
4 h after i.v. injection with Alexa-488-EV peptide formulated in LCC-PEG or LCC-PEG-
AA NPs (a). Imaging was performed with use of an IVIS 100 imaging system.
Quantification of the total average fluorescence intensity (tumor area x fluorescence
intensity) of the tumors from each mouse group was estimated using Image J software (b).
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Tumor growth retardation effect of EV peptide. Nude mice bearing human H460 tumor were
i.v. injected (0.36 mg/kg) every other day with either PBS, free EV peptide, or EE or EV
peptide formulated in LCC-PEG-AA NPs. *: P < 0.05, Mean ± SEM (n=4–5).
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